Others explain that they needed to increase their dose because hunger returned or weight loss slowed
Its gaining popularity in the weight loss community and has even been called the next new wonder drug by many weight loss experts
However, thanks to the present results, and the SOUL cardiovascular outcomes trial of oral semaglutide confirming cardiovascular benefits in people with type 2 diabetes and CVD (McGuire et al, 2025), we now have more evidence-based drug options for the people we support
This analysis examines the evidence supporting dual agonism through the clinical development of tirzepatide, focusing on its efficacy, safety profile, and mechanistic rationale
This action on fat metabolism may contribute to weight loss beyond the effects of appetite suppression alone and may also underlie some of the improvements seen in lipid profiles and conditions like MASH
Discuss these options with your healthcare provider if prevention strategies alone are not sufficient